FDA Alerts
FDA: Don't Take Diamond 3500
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Diamond 3500, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
FDA Warns Against Sex Enhancement Pill
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Eros Power Zone 1900, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
ED Supplement May Pose Health Risk
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Triple MiracleZen Gold 1750 mg, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
Male Enhancement Product May Pose Health Risk
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Xtra Zone 2400, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
FDA: Diabetes Rx May Pose Serious Health Risk
The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.
Voluntary Recall of Specified Lots of Nova Max Glucose Test Strips
Nova Diabetes Care today announced it is initiating a voluntary recall of 21 lots of the Nova Max Glucose Test Strips distributed both in the USA and outside the continental USA. Nova Max® Plus™ glucose meter kits that include test strips from the recalled lots are also included in this voluntary recall.
FDA Alerts Companies to Stop Illegal Sale of Treatments for Diabetes
The US Food and Drug Administration is taking action to remove from the market illegal products, including some labeled as dietary supplements, that claim to mitigate, treat, cure or prevent diabetes and related complications.
FDA: Blood Pressure Medication Warning
The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) in patients with diabetes or kidney (renal) impairment.
FDA Recall of Insulin Delivery Device
The FDA is recalling Roche's ACCU-CHEK FlexLink Plus infusion set, a tool used to deliver insulin to diabetic patients.
A Kinked Cannula
Roche Insulin Delivery Systems announced today that it is notifying its customers and healthcare professionals about the recall of the ACCU-CHEK FlexLink Plus infusion set.